title: Subcutaneous injection containing IL-3 and GM-CSF ameliorates stab wound-induced brain injury in rats.
abstract: Macrophage-like cells densely accumulate in stab wound-induced brain lesions in rats. Many of these cells express the macrophage marker Iba1 and the oligodendrocyte progenitor cell marker NG2 chondroitin sulfate proteoglycan (NG2), and have been termed BINCs (brain Iba1(+)/NG2(+) cells). Results from our previous study showed that BINCs elicit neuroprotective action, and agents inducing BINC activation or proliferation are expected to ameliorate traumatic brain injuries (TBIs). In the present study, TBI was established by inserting a needle into the cerebrum and moving the needle in a longitudinal, fan-like movement. Isolated BINCs from these stab lesions expressed mRNAs encoding receptors for interleukin-3 (IL-3) and granulocyte/macrophage colony-stimulating factor (GM-CSF). When this mixture of cytokines was added to the cultured BINCs, expression of mRNAs encoding insulin-like growth factor-1, hepatocyte growth factor, and proliferating cell nuclear antigen increased. The cytokine mixture induced enhanced wound healing in BINCs-brain cell co-cultures in vitro. Stab wounds in the rats resulted in significant brain tissue loss at 2 months post-lesion. However, tissue loss was reduced by 40% when the combination of IL-3 and GM-CSF was subcutaneously injected 7 times (once per day) beginning at 2 or 3 days post-lesion (dpl). BINCs are highly proliferative and an intraperitoneal injection of 5-fluorouracil (5FU) at 2 dpl eliminated the BINCs, resulting in death of the rats. The cytokine mixture injection significantly reduced mortality of the 5FU-treated rats. These results suggest that the combination of IL-3 and GM-CSF serves as a promising agent to ameliorate TBI via action on BINCs.
authors.affiliation: Ehime Proteo-Medicine Research Center, Department of Basic and Clinical Neuroscience, Ehime University, Japan.
authors.forename: Tasuku
authors.initials: T
authors.lastname: Nishihara
authors.forename: Michihisa
authors.initials: M
authors.lastname: Ochi
authors.forename: Kana
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Hisaaki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Hajime
authors.initials: H
authors.lastname: Yano
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kumon
authors.forename: Takanori
authors.initials: T
authors.lastname: Ohnishi
authors.forename: Junya
authors.initials: J
authors.lastname: Tanaka
mesh_terms: D000818:Animals; D001930:Brain Injuries / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism / Q000627:therapeutic use*; D017228:Hepatocyte Growth Factor / Q000235:genetics / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000235:genetics / Q000378:metabolism; D007377:Interleukin-3 / Q000378:metabolism / Q000627:therapeutic use*; D008264:Macrophages / Q000378:metabolism / Q000473:pathology; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D016896:Treatment Outcome; D014945:Wound Healing / Q000502:physiology*
chemical_list: D007377:Interleukin-3; D018809:Proliferating Cell Nuclear Antigen; D012333:RNA, Messenger; D017228:Hepatocyte Growth Factor; D007334:Insulin-Like Growth Factor I; D016178:Granulocyte-Macrophage Colony-Stimulating Factor